Quanbo Zhou

8.1k citations
93 papers · 5.7k indexed · 4 hit papers · h-index 36

Quanbo Zhou

89 papers receiving 5.7k citations

Hit Papers

Pre-metastatic niche...802018202620202023200400600

Peers

Quanbo Zhou
Comparison fields: 5 of 118
  • Cancer Research 3.6k
  • Molecular Biology 4.3k
  • Oncology 1.2k
  • Immunology 610
  • Pulmonary and Respiratory Medicine 416
Replace Weitang Yuan with:
Weitang Yuan China
Zhenqiang Sun China
Minghui Wang China
Francesca Lovat United States
Mariano Monzó Spain
Lintao Jia China
Nehad M. Alajez Qatar
Hidayatullah G. Munshi United States
Michela Garofalo United States
Katsuhiro Uzawa Japan
Quanbo Zhou relative to Weitang Yuan China Weitang Yuan's profile →
Citations per field
00.5×9.5×
Weitang Yuan · 1×
Citations per year

Countries citing papers authored by Quanbo Zhou

Since Specialization
Citations

This map shows the geographic impact of Quanbo Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quanbo Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quanbo Zhou more than expected).

Fields of papers citing papers by Quanbo Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quanbo Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quanbo Zhou. The network helps show where Quanbo Zhou may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Quanbo Zhou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Quanbo Zhou Line = papers co-authored together Quanbo Zhou links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20251
3 20250
4 20246
5 20246
6 20247
7 20241
8 202334
9 202313
10 202325
11 202346
12 202251
13 202157
14 20214
15 202033
16 20201
17 20191
18 2018134
19 201622
20
[Human mucin 1 promoter drives human sodium/iodide symporter gene targeting expression in pancreatic carcinoma cells].
20071

About Quanbo Zhou

Quanbo Zhou is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 93 papers that have together received 5.7k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (25 papers), Pancreatic and Hepatic Oncology Research (22 papers), MicroRNA in disease regulation (18 papers), RNA modifications and cancer (16 papers), Circular RNAs in diseases (14 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), Extracellular vesicles in disease (8 papers) and Cancer-related gene regulation (7 papers). The work is most often cited by research in Cancer Research (3.6k citations), Molecular Biology (4.3k citations) and Oncology (1.2k citations). Quanbo Zhou has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Weitang Yuan, Guixian Wang, Jinbo Liu, Zhenqiang Sun, Qing Lin, Shuaixi Yang, Shangyou Zheng, Junmin Song, Huilin Ye and Weiwei Wang. Their work appears in journals such as Nature Genetics, Journal of Clinical Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026